---
document_datetime: 2023-09-21 18:20:45
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/bondronat-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: bondronat-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.4171518
conversion_datetime: 2025-12-25 07:32:36.503469
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Steps taken after granting the Marketing Authorisation

For procedures finalised after 1 September 2004 please refer to module 8B.

- On  30  August  1996  the  Marketing  Authorisation  Holder  submitted  an  application  for  two variations (Type I) relating to changes in the manufacture and changes in test procedures of the medicinal  product.  The  procedure  started  on  12  September  1996.  These  variations  were approved  by  the  EMEA  on  11  October  1996  and  did  not  require  any  amendments  to  the Commission Decision. Changes were introduced in the chemical, pharmaceutical and biological documentation of the dossier. The section III.2 of this EPAR has been amended accordingly.
- On 17 July 1996 the CPMP adopted a positive Opinion on an application for an extension of the Marketing  Authorisation  to  a  new  strength  (2  mg/2  ml)  for  Bondronat  submitted  by  the Marketing  Authorisation  Holder.  The  European  Commission  on  25  October  1996  issued  a favourable Decision.
- On 11 March 1997 the Marketing Authorisation Holder submitted an application for a Type II variation in connection with addition of a pack size of 1 ampoule to the already approved pack size  of  5  ampoules.  The  CPMP adopted a positive Opinion on 16 April 1997. The European Commission on 27 August 1997 issued a favourable Decision.
- On 21 May 1998 the Marketing Authorisation Holder submitted an application  for  a  Type  I variation relating to changes in the specifications and test procedures of the active substance. The  procedure  started  on  29  May  1998.  This  variation  was  approved  by  the  EMEA  on 10 June 1998 and did not require any amendments to the Commission Decision. Changes were introduced in the chemical, pharmaceutical and biological documentation of the dossier.
- On 20 November 1998 the Marketing Authorisation Holder submitted two applications for two Type  I  variations  relating  to  changes  in  the  test  procedures  of  the  medicinal  product.  The procedure  started  on  27  November  1998.  The  variations  were  approved  by  the  EMEA  on 18 December 1998 and did not require any amendments to the Commission Decision. Changes were introduced in the chemical, pharmaceutical and biological documentation of the dossier.
- On  12 January 1999  the  Marketing  authorisation  Holder  submitted  an  application  for  the transfer  of  the  Marketing  Authorisation  for  Bondronat  from  Boehringer  Mannheim  GmbH  to Roche Registration Limited, United Kingdom. The transfer was approved by the EMEA. The EMEA  notified  the  European  Commission,  who  amended  the  Commission  Decision  on 29 March 1999.
- On 12 January 1999 the Marketing Authorisation Holder submitted an application for a Type I variation  relating  to  changes  in  the  name  of  the  manufacturer  of  the  medicinal  product  and subsequent  change  in  the  name  of  the  manufacturer  of  the  active  substance.  The  procedure started on 26 January 1999. The variation was approved by the EMEA on 9 February 1999. This variation  required  amendments  in  the  relevant  sections  of  the  Commission  Decision.  The European Commission amended the Decision on 11 May 1999 .
- On 19  July  1999  the  Marketing  Authorisation  Holder  submitted  an  application  for  a  Type  I variation for a change in the shelf-life of the medicinal product. The procedure started on 19 July 1999. The variation was approved by the EMEA on 5 August 1999. This variation required amendments in the relevant sections of the Commission Decision. The European Commission amended the Decision on 16 November 1999 .
- In accordance with Article 10(3) of Council Directive 92/27 EEC of 31 March 1992, the EMEA issued  on  5  August  1999  a  Notification  for  amendment  of  the  addresses  of  the  local representatives  included  in  the  package  leaflet  as  applied  for  by  the  MAH.  The  Commission amended the Commission Decision on 16 November 1999.
- On  10  April  2000  the  Marketing  Authorisation  Holder  submitted  a  Corrigendum  to  the Commission Decision dated 16 November 1999 for the Dutch SPC (section 4.3), Finnish SPC (section 6.4) and Portuguese SPC (section 5.2). This Corrigendum required amendments to the relevant  sections  of  the  Commission  Decision.  The  European  Commission  amended  the Decision on 11 August 2000.
- In accordance with Article 10(3) of Council Directive 92/27 EEC of 31 March 1992, the EMEA issued on 10 May 2000 a Notification for amendment of the Greek and Portuguese addresses of the local representatives included in the package leaflet as applied for by the MAH. A change has also been made to the Spanish version in which the strength mentioned in section 5 of the Package Leaflet has been corrected from 1 mg/ 1 ml to 2 mg/ 2 ml. The Commission amended the Commission Decision on 27 June 2000.

<div style=\"page-break-after: always\"></div>

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                            | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|--------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Change in pack size for a medicinal product                                                      | I/16                 | I                        | 23.02.01                            | 23.04.01                                 |
| Extension new strength                                                                           | X/17                 | X                        | 29.03.01                            | 13.09.01                                 |
| 5-year Renewal of the Marketing Authorisation                                                    | R/18                 | R                        | 25.04.01                            | 12.09.01                                 |
| Update of Summary of Product Characteristics sections 4.6 and 5.3                                | II/19                | II                       | 25.04.01                            | 12.09.01                                 |
| Update of Summary of Product Characteristics sections 4.5 and 5.2 and Package Leaflet section 2  | II/20                | II                       | 25.04.01                            | 12.09.01                                 |
| Change in test procedures of the medicinal product                                               | I/21                 | I                        | 30.08.02                            | 10.09.02                                 |
| Extension of Indication                                                                          | II/22                | II                       | 24.07.03                            | 07.11.03                                 |
| Addition of a new pharmaceutical form                                                            | X/23                 | X                        | 24.07.03                            | 24.10.03                                 |
| New presentation(s)                                                                              | II/25                | II                       | 24.07.03                            | 31.10.03                                 |
| Change in shelf-life of finished product - as packaged for sale                                  | IB/26                | IB                       | 12.01.04                            | -                                        |
| Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | N/27                 | N                        | 30.03.04                            | -                                        |
| Change in shelf-life of finished product - as packaged for sale                                  | IB/31                | IB                       | 17.06.04                            | -                                        |